posted on 2025-06-03, 05:28authored byLori M Laffel, Thomas Danne, Georgeanna J. Klingensmith, Elke Schueler, Igor Tartakovsky, Laurieann Nessralla, Philip Zeitler, Steven Willi
This is the supplemental material for the publication 'A comparison of SGLT2 or DPP-4 inhibitor monotherapy vs placebo for type 2 diabetes in adolescents vs young adults ' in the journal JES.
Funding
The DINAMO and DINAMO MONO trials (NCT03429543), as well as the young adults trial (NCT01177813) were funded by the Boehringer Ingelheim and Eli Lilly and Company Alliance.